Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalanci ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results